Agouron and Roche jointly to develop anti-cancer agents Thymitaq and AG3340.
Executive Summary
AGOURON & ROCHE TO DEVELOP THYMITAQ, AG3340 CANCER DRUGS and collaborate on discovering other early-stage anti-cancer therapies, the companies announced June 20. Under the letter-of-intent stage agreement, the initial target enzyme of the collaboration will be cdk4 (cyclin dependent kinases).